Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Dyskinesia caused by L-DOPA].

P Derkinderen1, M Vidailhet

  • 1Service de Neurologie, Hôpital Saint-Antoine, 75012 Paris.

Revue Neurologique
|April 15, 2003
PubMed
Summary
This summary is machine-generated.

L-DOPA-induced dyskinesias affect many Parkinson's patients, often starting as foot dystonia. Factors like age and L-DOPA dose influence their development, with striatal synaptic plasticity a suspected cause.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The multiple twists in the tale: Brain iron accumulation, facial jerks, and truncal dystonia: Expert commentary.

Parkinsonism & related disorders·2022
Same author

Dopamine denervation in the functional territories of the striatum: a new MR and atlas-based <sup>123</sup>I-FP-CIT SPECT quantification method.

Journal of neural transmission (Vienna, Austria : 1996)·2021
Same author

Validation of a non-motor fluctuations questionnaire in Parkinson's disease.

Revue neurologique·2021
Same author

Pathophysiology of Parkinson's disease: Mitochondria, alpha-synuclein and much more….

Revue neurologique·2020
Same author

STW5 (Iberogast®) for constipation in Parkinson's disease.

Revue neurologique·2020
Same author

Movement disorders as a new neurological clinical picture in severe SARS-CoV-2 infection.

European journal of neurology·2020
Same journal

Geographic disparities in MRI features of ischemic stroke and small vessel disease: A comparative study between French Guiana and mainland France. Findings from the BECATOUR multicenter registry.

Revue neurologique·2026
Same journal

Continuous subcutaneous perfusion of apomorphine in Parkinson's disease: Towards monotherapy?

Revue neurologique·2026
Same journal

Neuro-Whipple presenting as autoimmune encephalitis.

Revue neurologique·2026
Same journal

Multimodal assessment of minimally conscious state and cognitive motor dissociation in neurocritical care: A critical review.

Revue neurologique·2026
Same journal

Development of a new episodic memory assessment tool (NEM): Preliminary data and clinical perspectives.

Revue neurologique·2026
Same journal

Novel variants and rare clinical presentations in MFN2-related Charcot-Marie-Tooth disease: Insights from 10 families.

Revue neurologique·2026
See all related articles

Area of Science:

  • Neurology
  • Pharmacology

Context:

  • L-DOPA is a primary treatment for Parkinson's disease.
  • L-DOPA-induced dyskinesias (LID) are a common and debilitating side effect.
  • Approximately one-third of patients develop LID within five years.

Purpose:

  • To summarize the clinical presentation, contributing factors, and potential pathophysiology of L-DOPA-induced dyskinesias.
  • To highlight the challenges in classifying and assessing LID.

Summary:

  • LID commonly manifest as dystonia, often starting in the foot, and can be categorized as off dystonia, diphasic, or peak-dose dyskinesia.
  • Key factors correlating with LID development include young age of onset, disease severity, treatment duration, and L-DOPA dosage.
  • While the exact mechanisms are unclear, synaptic plasticity in striatal neurons is implicated. Existing rating scales for LID assessment are still under evaluation.

Related Experiment Videos

Impact:

  • Provides a concise overview of LID for clinicians and researchers.
  • Identifies critical factors for predicting and potentially mitigating LID.
  • Underscores the need for further research into LID pathophysiology and improved assessment tools.